[Pharmacoeconomical rationale for switching of patients with type 1 diabetes mellitus to the short-acting insulin analogue Aspart (Novorapid*)].
The consequences of switching of patients with type 1 diabetes mellitus (DM-1) to the short-acting insulin analogue Aspart (Novorapid*) were pharmacoeconomically analyzed. The study has indicated that switching of patients with DM-1 to the short-acting insulin analogue Aspart leads in actual practice to the decreased levels of Hb Ak due to its pharmacological properties ensuring the maximum simulation of physiological pancreatic insulin secretion, which is followed by a reduction in the absolute risk of new cases and by progression of existing chronic vascular complications as compared with the use of short-acting insulin analogue Actrapid. Calculation of the cost of treatment of all prevented vascular complications due to DM has shown that the short-acting insulin analogue Novorapid is more cost-effective agent than Actrapid.